Story Poster

Betters Eye UGA's Growing Odds

September 10, 2019
3,720

ATHENS - Not that it is a surprise, but Georgia will be favored in each game it plays from here on out… according to the WiseGuys in Vegas. 

The Westgate Las Vegas updated a slew of games on Tuesday, and the Bulldogs were featured in several of them. Listed in a package of “Games of the Year”, Georgia is listed as at least a touchdown favorite from here out out against all comers. 

That’s a substation declaration. 

The book now lists the Dawgs as favorites to win by the following margins:

Sept. 21 - Notre Dame at UGA (-11.5)
Nov. 2 - Florida vs. UGA (-7.5)
Nov. 16 - UGA at Auburn (+11)
Nov. 23 - Texas A&M at UGA (-12)
Nov. 30 - UGA at Tech (+24)

Kirby Smart is 27-2 straight up as a double-digit favorite (2016 Vanderbilt +14; 2018 Texas +13.5), which indicates the Bulldogs are probably in pretty good shape on that front. 

But the game against the Gators stands out. That line has moved towards UGA over the last few months as it was once about a four-point line, but is now nearly double that. Could that have been because of the Gators’ season-opening performance against Miami?

The Bulldogs are 7-3 under Kirby as touchdown or fewer favorites (2016 Tech +4.5; 2017 at Auburn +2.5; 2018 at LSU +7). If the line against the Gators moves to at least eight points, but under ten, UGA is undefeated in those contests under Kirby (3-0). 

There are some other interesting lines to take note of that were released Tuesday as well. 

Sept. 21 - Tennessee at Florida (-17)
Sept. 21 - Michigan at Wisconsin (+1.5)
Oct. 5 - Auburn at Florida (-6.5)
Oct. 12 - USC at Notre Dame (-10.5)
Oct. 12 - Florida at LSU (-10.5)
Oct. 12 - Texas vs. Oklahoma (-10)
Oct. 19 - Oregon at Washington (-1.5)
Oct. 26 - Notre Dame at Michigan (-6)
Nov. 9 - LSU at Alabama (-11.5)
Nov. 30 - Ohio State at Michigan (-2)
Nov. 30 - Alabama at Auburn (+17)
Nov. 30 - Texas A&M at LSU (-10)

 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.